What is iFyber?
iFyber operates as a sophisticated preclinical contract research organization, bridging the critical gap between laboratory innovation and commercial application. The firm distinguishes itself through a multidisciplinary approach that synthesizes chemistry, biology, and materials science to address complex R&D challenges. Their service portfolio is comprehensive, encompassing microbial control, biofilm testing, and antimicrobial efficacy assessments. By catering to high-stakes sectors such as medical devices, advanced wound care, diagnostics, and specialty textiles, iFyber provides the technical rigor necessary for clients to navigate stringent regulatory and development pathways. Their market position is defined by a commitment to personalized, high-expertise support, ensuring that clients receive bespoke analytical solutions tailored to specific material and biological requirements.
How much funding has iFyber raised?
iFyber has raised a total of $378K across 2 funding rounds:
Debt
$150K
Debt
$228K
Debt (2020): $150K with participation from PPP
Debt (2021): $228K led by PPP
Key Investors in iFyber
PPP
Public-Private Partnership
What's next for iFyber?
With the recent influx of capital, iFyber is well-positioned to scale its service offerings and enhance its laboratory infrastructure. The strategic focus will likely shift toward expanding its analytical capabilities to meet the increasing demand for advanced antimicrobial testing and material characterization. As the company moves deeper into its late-stage lifecycle, the emphasis will remain on operational excellence and the cultivation of long-term partnerships within the medical device and textile industries. By maintaining its focus on high-value, specialized research, iFyber is poised to capture additional market share, further cementing its reputation as a vital partner for organizations seeking to accelerate their product development cycles through rigorous, science-led methodology.
See full iFyber company page
